Newsletter

Menu

Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street

By Staff Correspondent |

Pfizer Inc.’s (NYSE: PFE) shares continue to trade in red after the company narrowly missed revenue estimates for the second quarter of 2019. Adjusted EPS topped expectations. The company’s stock was down 2.17% in premarket hours on Tuesday.

Total revenues fell 2% year-over-year to $13.3 billion, missing the consensus estimate of $13.4 billion. Revenue results reflect an unfavorable impact from foreign exchange of 4%, which offset operational growth of 2%.

Pfizer beat earnings estimates for Q2 2019 but missed on revenue

Reported net income rose 30% to $5 billion, or $0.89 per share, compared to the prior-year quarter. Adjusted income decreased 2% to $4.5 billion while adjusted EPS rose 4% to $0.80, beating forecasts of $0.75.

During the quarter, revenue in the Biopharma business grew 2% to $9.6 billion, driven by growth in key brands such as Ibrance, Xeljanz and Eliquis. The growth was partially offset by lower revenues from Enbrel and Prevnar 13. Revenues in the Upjohn segment fell 11% to $2.8 billion, hurt by declines in the US and China. Consumer Healthcare segment revenues fell 3% to $862 million.   

Pfizer updated its guidance for fiscal year 2019 to reflect the formation of its JV with GlaxoSmithKline plc and the expected completion of the Array BioPharma acquisition. The company now expects revenues of $50.5-52.5 billion versus the prior outlook of $52-54 billion. Adjusted EPS is estimated to be $2.76-2.86 compared to the previous range of $2.83-2.93.

Pfizer also announced an agreement to combine its Upjohn business with Mylan NV (NASDAQ: MYL), creating a new global pharmaceutical company. The agreement is structured as an all-stock, Reverse Morris Trust transaction and is expected to close in mid-2020. Pfizer’s shareholders will own 57% of the combined company and Mylan’s shareholders will own 43%.

Michael Goettler will be the Chief Executive Officer of the new entity. The new company is expected to have pro forma 2020 revenues of $19-20 billion. Pro forma 2020 adjusted EBITDA is estimated to be $7.5-8.0 billion, including phased synergies of approx. $1 billion annually to be realized by 2023. Pro forma free cash flow for 2020 is expected to be more than $4 billion.

Pro forma for the separation of the Upjohn business, Pfizer expects to generate 2020 revenues of approx. $40 billion.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Advertisement

More on this Company

Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025

January 21, 2026

Johnson & Johnson heads into Q4 as a more focused healthcare leader

January 12, 2026
ipo news

Everything you need to know about Aktis Oncology’s upcoming IPO

December 26, 2025

50 responses to “Pfizer’s stock suffers as Q2 results and Mylan deal fail to impress Wall Street”

  3. aimbot cs2

    […]please check out the sites we follow, which includes this one particular, as it represents our picks through the web[…]

  15. family ho

    […]we prefer to honor a lot of other internet web-sites on the net, even when they aren’t linked to us, by linking to them. Below are some webpages worth checking out[…]

  20. we buy puppies

    […]we like to honor a lot of other net web sites around the internet, even though they aren’t linked to us, by linking to them. Underneath are some webpages worth checking out[…]

  21. linh hoang

    […]very couple of sites that take place to be detailed beneath, from our point of view are undoubtedly nicely really worth checking out[…]

  26. sui

    […]very couple of web-sites that take place to become in depth beneath, from our point of view are undoubtedly very well really worth checking out[…]

  27. playnet

    […]we prefer to honor lots of other world-wide-web sites around the internet, even if they aren’t linked to us, by linking to them. Under are some webpages really worth checking out[…]

  33. How To Get My Dog Papers

    […]Wonderful story, reckoned we could combine several unrelated data, nevertheless genuinely really worth taking a search, whoa did one particular discover about Mid East has got much more problerms too […]

  34. Dog Registry

    […]that may be the finish of this article. Right here you will come across some sites that we believe you will appreciate, just click the hyperlinks over[…]

  36. Dog Papers

    […]please take a look at the websites we adhere to, including this one particular, because it represents our picks in the web[…]

  37. Dog Papers

    […]although web sites we backlink to beneath are considerably not connected to ours, we really feel they may be really really worth a go via, so possess a look[…]

  38. sugar land seo company

    […]Wonderful story, reckoned we could combine a number of unrelated data, nonetheless genuinely worth taking a look, whoa did one particular learn about Mid East has got additional problerms also […]

  48. bjj houston tx

    […]just beneath, are numerous totally not related web sites to ours, nevertheless, they’re certainly worth going over[…]

  49. mexican candy shop

    […]that would be the end of this report. Right here you’ll come across some internet sites that we feel you’ll enjoy, just click the hyperlinks over[…]

Top